Advertisement

Topics

US FDA grants fast track designation to CRISPR & Vertex's CTX001 to treat sickle cell disease

14:14 EST 7 Jan 2019 | PharmaBiz

CRISPR Therapeutics and Vertex Pharmaceuticals Incorporated announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation for CTX001 for the treatment of sickle cell

Original Article: US FDA grants fast track designation to CRISPR & Vertex's CTX001 to treat sickle cell disease

NEXT ARTICLE

More From BioPortfolio on "US FDA grants fast track designation to CRISPR & Vertex's CTX001 to treat sickle cell disease"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...